๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease

โœ Scribed by Ondo, W. G.; Hunter, C.; Moore, W.

Book ID
127123967
Publisher
Lippincott Williams and Wilkins
Year
2004
Tongue
English
Weight
149 KB
Volume
62
Category
Article
ISSN
0028-3878

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Safety and efficacy of botulinum toxin t
Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: A prospective double-blind trial
โœ Robert Chinnapongse; Kristen Gullo; Paul Nemeth; Yuxin Zhang; Lynn Griggs ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 854 KB

## Abstract Sialorrhea (drooling) is a common symptom of Parkinson's disease (PD) that can significantly impair a patient's health and quality of life. Fiftyโ€four PD subjects with troublesome sialorrhea were enrolled using a multicenter, randomized, doubleโ€blind, sequentialโ€dose escalation design i

Botulinum toxin type A for drooling in P
Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study
โœ Giovanni Lagalla; Marzia Millevolte; Marianna Capecci; Leandro Provinciali; Mari ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 65 KB

To investigate the safety and efficacy of botulinum toxin type A (BoNTX) treatment to reduce sialorrhea in Parkinson's disease (PD), a double-blind, randomized, placebo-controlled study enrolled 32 PD patients complaining of excessive drooling. Patients received either 50 U Botox in each parotid gla

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease
โœ Kitty K. Wong; Jane E. Alty; Amanda G. Goy; Sanjay Raghav; David C. Reutens; Pet ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 565 KB

## Abstract ## Background: This randomized double blind, placeboโ€controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease. ## Methods: Sixteen participants with levodopaโ€induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments s